Amoxicillin-Clavulanate

C difficile risk
High
Oral Bioavailability
Excellent

Dosing

  • 875 mg PO q12h OR

  • 500 mg PO q8h

Dose listed as amoxicillin component Less diarrhea with 875 mg given q12h vs. 500 mg q8h

CrCl 30-49 CrCl 10-29CrCl <10- 500 mg PO q8h

  • 875 mg PO q12h

Dose listed as amoxicillin component Less diarrhea with 875 mg given q12h vs. 500 mg q8h500 mg PO q12h

Dose listed as amoxicillin component Do not use 875 mg tablets if CrCl less than 30 mL/min500 mg PO q24h

Dose listed as amoxicillin component Do not use 875 mg tablets if CrCl less than 30 mL/min

500 mg PO q24h

Dose listed as amoxicillin component Administer dose after dialysis on dialysis days

General Information

Prophylaxis and treatment of human and animal bite wounds.

Polymicrobial infections involving the respiratory tract or abdomen.

For prolonged therapy, monitor liver enzymes and function.

  •  Allergy/rash (immediate or delayed)

  •  Note EBV related rash

  •  Cytopenias

  •  Diarrhea (less likely with twice daily dosing regimen using 875 mg tab)

  • C. difficile

  •  Hepatotoxicity due to clavulinate - usually mild, liver failure is rare.

Increased risk of rash with allopurinol

Antimicrobial class: Aminopenicillin + Beta-lactamase inhibitor

Pregnancy category: B

Average serum half life: 1 hour

Urine penetration: Therapeutic

Lung penetration: Therapeutic

Biliary penetration: Therapeutic

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.